Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-05-26

FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE EXTENDED-RELEASE — Supplemental Application (Vitruvias Therapeutics, Inc.)

View source ↗

Summary

The FDA approved a supplemental application to market an extended-release formulation of pramipexole dihydrochloride by Vitruvias Therapeutics, Inc., for the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pramipexole dihydrochloride extended-release (pramipexole dihydrochloride)

Snippet

SUPPL AP for PRAMIPEXOLE DIHYDROCHLORIDE EXTENDED-RELEASE (PRAMIPEXOLE DIHYDROCHLORIDE)